Clinical Trial

Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission

Study acronym: HOVON164HL
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This trial investigates the efficacy and safety of the drug tislelizumab in combination with chemotherapy as a treatment for patients with R/R HL. Tislelizumab is given in combination with chemotherapy (gemcitabine and cisplatin) followed by consolidation with tislelizumab alone. The study primary question is whether this strategy works as well as the standard treatment with intensive chemotherapy and autologous stem cell transplant.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-08-12; most recent amendment 2026-03-05.
Status change: Recruiting → Active, Not Recruiting 2026-03-05
Status change: Not Yet Recruiting → Recruiting 2023-07-14
Trial Details
NCT Number NCT05502250
Lead Sponsor Stichting Hemato-Oncologie voor Volwassenen Nederland
Collaborators: Danish Lymphoma Group
Conditions Hodgkin Lymphoma
Enrollment 75 participants
Start Date 2023-07-14
Primary Completion 2028-03 (estimated)
Study Completion 2031-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-06